Aqemia, a Paris, France-based next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipelines, raised €30 million in a Series A funding.
The round was led by Eurazeo and Bpifrance through its Large Venture fund, with the participation from Elaia.
This financing will further support Aqemia's core mission: to massively scale drug discovery through a first-in-class technological platform combining quantum-inspired physics and machine learning.
"After repeated successes in generating very efficiently innovative new chemical matter in collaboration with large pharmaceutical companies around the world, we are now excited to leverage this fundraising to accelerate towards Aqemia's mission: build a massive pipeline of wholly-owned drug discovery projects.", said Maximilien Levesque, Co-founder, and CEO of Aqemia.
Aqemia's ambition is to optimize and accelerate early drug discovery projects on a massive scale to uncover dozens of proprietary new drug candidates.
Round: Series A
Funding Month: October 2022
Lead Investors: Eurazeo and Bpifrance
Additional Investors: Elaia
Company Website: https://www.aqemia.com/
Software Category: AI-Enabled Drug Discovery Pipeline
About the Company: Founded in 2019 as a deeptech spin-off from École normale supérieure, Aqemia is a next-generation pharmatech company generating one of the growing drug discovery pipelines. Its mission is to scale the drug discovery process by leveraging a unique-in-the-world technology combining quantum-inspired physics and machine learning. In only three years, the company has grown to an amazing team of 50+ people, built and repeatedly extended collaborations with large pharmaceutical companies, and started its drug discovery pipeline with multiple projects ranging from hit generation to vivo assays. Aqemia's goal is to massively accelerate research projects to scale to dozens of wholly or partly owned drug candidates, placed into a constellation of biotech spin-offs to carry out the clinical trials.